Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity and Treatment Regimens of VTP-300 Combined With Low-dose Nivolumab in Chronic Hepatitis B Infection

NCT05343481 is registered in ClinicalTrials.gov with Barinthus Biotherapeutics as lead sponsor.

NCT NCT05343481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05343481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity and Treatment Regimens of VTP-300 Combined With Low-dose Nivolumab in Chronic Hepatitis B Infection
Lead sponsor
Barinthus Biotherapeutics
Phase
Phase 2
Overall status
Completed
Start date
September 21, 2022
Completion date
January 13, 2026
Enrollment
121 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b